List of Excipients in Branded Drug LACTULOSE

Generic Drugs Containing LACTULOSE

Company	Ingredient	NDC	Excipient
Xttrium Laboratories Inc	lactulose	0116-4005	D&C YELLOW NO. 10
Xttrium Laboratories Inc	lactulose	0116-4005	FD&C YELLOW NO. 6
Xttrium Laboratories Inc	lactulose	0116-4005	WATER

What are the Most Frequently-Used Excipients in LACTULOSE?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10
1	D&C YELLOW NO. 6
3	FD&C BLUE NO. 1

Lactulose Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Lactulose is a mature, low-cost disaccharide drug with limited composition-of-matter exclusivity and substantial generic competition. Commercial opportunities are concentrated in excipient optimization, taste masking, single-dose packaging, pediatric adherence, low-sugar positioning, manufacturing efficiency, and differentiated delivery formats rather than in new chemical-entity protection.

What is lactulose and where is it used?

Lactulose is a synthetic disaccharide composed primarily of galactose and fructose. It is administered orally as a solution or syrup and is used for two principal indications:

1. Constipation, where it acts as an osmotic laxative.
2. Reduction of intestinal ammonia absorption in patients with portal-systemic encephalopathy, including hepatic encephalopathy.

The FDA labeling for lactulose oral solution typically specifies a dose volume containing 10 grams of lactulose per 15 mL. The drug reaches the colon largely undigested, where bacterial metabolism produces organic acids that increase osmotic activity and acidify colonic contents. This mechanism supports both stool softening and reduced ammonia absorption. (U.S. Food and Drug Administration [FDA], 2023a)

Lactulose is generally supplied as a concentrated aqueous solution. Its formulation profile is therefore driven by palatability, viscosity, microbial control, packaging, dose accuracy, and chemical stability rather than by solubility enhancement.

What excipients are used in lactulose formulations?

The active ingredient is usually delivered in a water-based syrup containing residual or associated sugars. Commercial lactulose products may contain lactose, galactose, fructose and other sugars resulting from the manufacturing process, together with purified water and, in some products, flavoring agents.

Typical excipient functions

Excipient or formulation component	Primary function	Commercial relevance
Purified water	Vehicle	Controls concentration, viscosity and dose volume
Lactose and galactose	Process-related sugars or residual carbohydrates	Important for labeling and patient counseling
Fructose or other sugars	Process-related impurities or sweetening contribution	Affects diabetic-use positioning and palatability
Flavoring agents	Taste masking	Supports pediatric and chronic-use adherence
Acidity regulators	pH control	May improve stability and sensory performance
Preservative system, where used	Microbial control	Relevant for multidose bottles and in-use stability
Sweeteners or polyols	Taste modification and sugar reduction	Potential differentiation area
Suspending or thickening agents	Texture and dose perception	Must not compromise dose uniformity or administration

The excipient strategy must distinguish between intentionally added excipients and sugars that arise from the lactulose manufacturing process. The latter can affect product specifications, impurity controls, nutritional labeling, and use in patients with diabetes or hereditary carbohydrate-intolerance disorders.

FDA labeling for lactulose products has historically warned that the solution may contain small amounts of galactose and lactose. That point is commercially relevant because the patient population may include individuals with carbohydrate metabolism disorders, diabetes, or dietary restrictions. (FDA, 2023a; FDA, 2023b)

What excipient strategy is most attractive for lactulose?

The strongest strategy is a platform approach with separate formulations for adult chronic use, pediatric use, institutional use and hepatic encephalopathy.

1. Taste masking and sensory optimization

Lactulose has a characteristic sweet taste and can cause bloating, flatulence and abdominal discomfort. A formulation that improves taste without increasing gastrointestinal burden has a direct adherence benefit.

Potential approaches include:

• Citrus, berry or neutral flavor systems.
• High-intensity sweeteners combined with lower sugar content.
• Polyol-based taste modulation, subject to gastrointestinal tolerance.
• Flavor encapsulation for powder or granule formats.
• Reduced-viscosity formulations that are easier to swallow and dilute.
• Oral dosing presentations that permit administration with water, juice or soft food.

The main development risk is that flavoring or sweetener changes can alter perceived potency, osmotic load, viscosity or gastrointestinal tolerability. The formulation should be evaluated using both sensory testing and pharmacodynamic tolerability endpoints.

2. Sugar-reduced and carbohydrate-controlled formulations

A low-sugar lactulose product could target patients who require long-term therapy and clinicians concerned about carbohydrate exposure. The positioning must be precise. Lactulose itself is a carbohydrate and remains the active ingredient. Removing process-related sugars does not create a sugar-free drug in the conventional nutritional sense.

The commercial claim should focus on:

• Reduced levels of lactose and galactose.
• Controlled residual carbohydrate specifications.
• Lower excipient sugar content.
• Improved suitability for selected dietary restrictions.

A sponsor should avoid implying that the product has no carbohydrate burden unless supported by formulation data and an appropriate regulatory review.

3. Single-dose sachets and stick packs

Single-dose packaging is one of the clearest commercial opportunities. Sachets can provide:

• Better dose portability.
• Lower contamination risk.
• Improved medication adherence.
• Easier hospital and long-term-care administration.
• Reduced measurement errors.
• A differentiated product presentation in a generic market.

A 10-gram unit-dose format would align with common dosing conventions, although hepatic encephalopathy dosing often requires repeated or titrated administration. Unit-dose packaging must therefore support dose adjustment, including multiple-sachet administration where appropriate.

For liquid products, unit-dose cups or oral dosing pouches can provide similar benefits but may have higher packaging costs and greater shipping weight. The commercial choice depends on whether the target market values convenience enough to absorb a premium over multidose bottles.

4. Pediatric and geriatric delivery

Pediatric and geriatric populations are commercially important because both groups can experience difficulty with volume measurement, swallowing and taste.

Useful design options include:

• Low-volume concentrates intended for dilution.
• Oral syringes with dose markings.
• Unit-dose oral cups.
• Flavor systems designed for repeated administration.
• A less viscous formulation for easier swallowing.
• Packaging that permits administration without transferring the drug to another container.

A low-volume concentrate can reduce administration burden, but it increases the risk of dosing errors. Any such product requires clear concentration labeling and device compatibility testing.

What formulations are protected by lactulose patents?

Lactulose is an old active pharmaceutical ingredient, and the original composition and therapeutic concepts are outside the period of modern composition-of-matter exclusivity. The principal competitive barriers are regulatory, manufacturing and commercial rather than basic molecule patents.

Composition-of-matter protection

No meaningful current composition-of-matter exclusivity should be assumed for lactulose. The molecule has been used medicinally for decades, and generic lactulose products are widely marketed.

Formulation patents

Potentially relevant patentable features could include:

• Novel taste-masking systems.
• Specific low-sugar impurity profiles.
• Stabilized liquid compositions.
• Preservative-free multidose systems.
• Unit-dose packaging.
• Powder or granule formulations for reconstitution.
• Pharmaceutical compositions combined with defined buffering systems.
• Device-assisted dosing systems.

Such claims would need to cover a measurable technical advantage. A patent directed only to the use of a conventional flavor in lactulose would face substantial validity and obviousness risk.

Method-of-use patents

Method-of-use opportunities are limited because the principal indications, including constipation and hepatic encephalopathy, are established. Narrow claims involving dosing schedules, administration protocols or patient subgroups may be possible, but enforcement value is likely to be modest unless the method produces a clinically meaningful and label-relevant advantage.

When does lactulose lose exclusivity?

Lactulose lost practical market exclusivity long ago. It is a generic small-molecule drug with multiple manufacturers and longstanding FDA approval history.

Exclusivity category	Lactulose position
New chemical entity exclusivity	Expired or not commercially relevant
Basic composition patent	Expired
Orphan-drug exclusivity	Not generally applicable to the core product
Pediatric exclusivity	No current strategic significance identified
Formulation exclusivity	Product-specific and potentially available only for a newly approved formulation
Data exclusivity for a new indication	Could arise only from a qualifying new approval
Generic competition	Established

The commercial consequence is that a new lactulose product would generally compete through formulation, packaging, supply reliability, channel access and price rather than through control of the active ingredient.

What is the Orange Book status of lactulose?

FDA-approved lactulose oral solutions are subject to the standard generic-drug framework. The FDA Orange Book can contain reference-listed-drug and therapeutically equivalent product information for approved lactulose formulations, but Orange Book status is product-specific and may change as applications are approved, withdrawn or updated. (FDA, 2024)

For diligence purposes, the key questions are:

• Which lactulose product is the reference listed drug?
• Which abbreviated new drug applications have therapeutic-equivalence ratings?
• Are any active patents or exclusivity periods listed for the relevant reference product?
• Does the proposed formulation differ sufficiently to require a new drug application rather than an abbreviated pathway?
• Are formulation or device claims listed in the Orange Book?

A standard generic oral solution is unlikely to create a durable patent position. A new dosage form or delivery system may require a separate regulatory strategy and may not automatically qualify for an abbreviated application.

Are Paragraph IV challenges relevant to lactulose?

Paragraph IV risk is likely to be limited for conventional lactulose oral solution because the core product is mature and genericized. Paragraph IV litigation becomes more relevant if a sponsor obtains approval for a differentiated formulation with listed patents.

Potential Paragraph IV targets could include:

• Unit-dose formulations.
• Modified-concentration solutions.
• Novel preservative systems.
• Powder-for-reconstitution products.
• Drug-device combinations.
• Specific low-sugar or impurity-controlled compositions.

A generic challenger could seek approval by arguing that a listed formulation patent is invalid, unenforceable or not infringed. For a mature product, the economic value of litigation depends on the sales base of the branded formulation. Small market size can limit settlement value and reduce the incentive for lengthy litigation.

Which companies compete in lactulose?

The market includes branded and generic manufacturers across North America, Europe and other regulated markets. Historical and current commercial brands have included Cephulac, Enulose and Generlac, together with private-label and generic lactulose oral solutions. Brand ownership and marketing rights have changed over time, so current commercial control must be checked against FDA application records and product listings.

Competitive dimensions

Competitive factor	Standard generic solution	Differentiated product
Price	Strong advantage	Usually higher
Palatability	Variable	Can be optimized
Packaging	Multidose bottle	Sachet, cup or device
Hospital use	Familiar and inexpensive	Requires formulary conversion
Pediatric adherence	Often limited	Strong opportunity
Patent position	Weak	Possible for technical formulation claims
Manufacturing complexity	Low to moderate	Moderate to high
Switching barrier	Low	Depends on clinical and operational benefit

The most credible competitors for a new product would be low-cost generic suppliers, branded specialty-pharmaceutical companies with hepatology channels, contract manufacturers with liquid-filling capability, and consumer-health companies experienced in laxative products.

What manufacturing and intellectual-property barriers affect lactulose?

Lactulose manufacturing is more important than the active ingredient’s patent estate. Commercial-grade production requires control of conversion chemistry, residual sugars, color, degradation products, concentration and microbial quality.

Manufacturing barriers

Key manufacturing considerations include:

• Consistent lactulose assay.
• Control of galactose, lactose and fructose levels.
• Color and odor control.
• Prevention of crystallization or concentration drift.
• Bulk-solution microbial control.
• Compatibility with high-barrier plastic or glass packaging.
• Stability after opening.
• Accurate filling of viscous liquids.
• Supply continuity for pharmaceutical-grade lactulose.

A supplier with strong impurity control may have a practical advantage even without enforceable patent protection. Specifications can also create switching friction if customers require tight residual-sugar limits or validated performance in sensitive patient populations.

Intellectual-property barriers

Potential IP barriers include:

• Manufacturing-process patents.
• Purification and impurity-removal claims.
• Low-color or high-purity lactulose compositions.
• Packaging systems.
• Flavor-masking combinations.
• Dosing devices.
• Combination products involving probiotics or other gastrointestinal agents.

Process patents can be commercially useful, but their value depends on whether the claimed process is necessary for economical production and whether infringement can be detected from the finished product.

How does lactulose compare with competing laxatives?

Lactulose competes with polyethylene glycol, magnesium-based products, stimulant laxatives, docusate and newer prescription therapies. In hepatic encephalopathy, it competes with rifaximin as an adjunctive or complementary therapy rather than as a direct substitute in every case.

Product class	Main advantage	Main limitation
Lactulose	Established use in constipation and hepatic encephalopathy	Taste, bloating, diarrhea and dosing burden
Polyethylene glycol	Broad constipation use and generally favorable palatability	Less established as the primary ammonia-lowering therapy
Magnesium salts	Low cost and rapid effect in selected patients	Electrolyte and renal safety concerns
Stimulant laxatives	Predictable short-term bowel stimulation	Less suitable for some chronic-use settings
Rifaximin	Important role in reducing recurrence of hepatic encephalopathy	High cost and antibiotic-related commercial considerations
Prescription secretagogues	Differentiated chronic constipation indications	Higher price and narrower use cases

Lactulose’s strongest protected commercial position is clinical familiarity in hepatic encephalopathy. Its weakest position is routine constipation, where many inexpensive alternatives are available.

What commercial opportunities exist for lactulose?

The most attractive opportunities are formulation-led:

1. Premium unit-dose sachets for hospitals, long-term-care facilities and travelers.
2. Pediatric flavored oral solutions with dose-calibrated devices.
3. Low-volume concentrates for patients unable to tolerate large liquid doses.
4. Reduced-residual-sugar formulations with transparent carbohydrate specifications.
5. Preservative-free single-use products.
6. Contract manufacturing and private-label supply.
7. Regional products adapted to local flavor, packaging and reimbursement requirements.
8. Digital adherence packaging linked to chronic hepatic encephalopathy management.

Revenue potential depends on whether the product can command a premium without losing formulary access. A low-cost generic bottle remains difficult to displace. A differentiated product needs a measurable benefit in adherence, dosing accuracy, hospital workflow or tolerability.

What generic launch risks exist for a new lactulose product?

Generic launch risk is high for a conventional oral solution and lower, but still material, for a differentiated presentation.

The main risks are:

• Rapid price erosion.
• Therapeutic interchangeability.
• Limited physician willingness to prescribe a premium product.
• Difficulty obtaining formulary placement.
• Low patient switching costs.
• Substitution by polyethylene glycol in constipation.
• Manufacturing failures involving color, assay or microbial quality.
• Patent claims that are too narrow to block design-around.
• Regulatory classification uncertainty for novel devices or combination products.

A commercially viable strategy should establish the target segment before development. A hospital unit-dose product, pediatric adherence product and hepatic-encephalopathy specialty product require different packaging, pricing and evidence plans.

Key Takeaways

• Lactulose is a mature generic drug with no meaningful current composition-of-matter exclusivity.
• Excipient value is concentrated in taste masking, viscosity control, sugar specification, preservation and packaging.
• Unit-dose sachets, oral cups and calibrated dosing devices offer the clearest commercial differentiation.
• A reduced-residual-sugar product could address labeling and tolerability concerns, but lactulose itself remains a carbohydrate.
• Conventional lactulose oral solution faces strong generic and therapeutic competition.
• Formulation and process patents may be available, but claims require a measurable technical advantage.
• Manufacturing control of residual sugars, color, concentration and microbial quality can create practical barriers.
• The strongest clinical franchise is hepatic encephalopathy; the most competitive market is routine constipation.
• Paragraph IV litigation is unlikely to be central unless a high-value differentiated formulation is successfully listed in the Orange Book.
• Commercial success depends more on adherence, administration efficiency and supply reliability than on active-ingredient patent protection.

FAQs

Is lactulose an excipient or an active pharmaceutical ingredient?

Lactulose is the active pharmaceutical ingredient in approved oral laxative and hepatic-encephalopathy products. It is not merely a sweetener or vehicle.

Can a lactulose product be marketed as sugar-free?

The claim requires careful qualification because lactulose is itself a carbohydrate. A product may have reduced lactose, galactose or other residual sugars, but "sugar-free" positioning requires regulatory and analytical support.

Is a lactulose sachet patentable?

A sachet alone is unlikely to support a strong patent. Patentability may improve if the sachet is part of a technically differentiated formulation involving stability, dose accuracy, moisture protection or improved administration performance.

Does lactulose require cold-chain distribution?

Standard lactulose oral solutions are generally distributed under controlled room-temperature conditions according to product-specific labeling. Cold-chain distribution is not ordinarily the core commercial requirement.

Is lactulose suitable for a 505(b)(2) product?

A 505(b)(2) strategy could be relevant for a materially different dosage form, concentration, device, administration method or formulation. A conventional lactulose oral solution would generally face a less differentiated regulatory pathway.

References

1. U.S. Food and Drug Administration. (2023a). Lactulose oral solution prescribing information. FDA-approved product labeling.

2. U.S. Food and Drug Administration. (2023b). Enulose lactulose solution prescribing information. FDA-approved product labeling.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. [Orange Book]. U.S. Department of Health and Human Services.

4. United States Pharmacopeia. (2024). Lactulose monograph. United States Pharmacopeial Convention.

5. European Medicines Agency. (2023). Lactulose-containing medicinal products: product information and regulatory documentation. European Union.